Quotient Limited (NASDAQ:QTNT) traded at a new 52-week low today of $3.36. Approximately 173,000 shares have changed hands today, as compared to an average 30-day volume of 477,000 shares.
There is potential upside of 12.9% for shares of Quotient Limited based on a current price of $3.45 and an average consensus analyst price target of $3.89.
Over the past year, Quotient Limited has traded in a range of $3.36 to $8.77 and is now at $3.45.
Quotient Ltd is a commercial-stage diagnostics company. It is involved in the business of provision of tests with an initial focus on blood grouping and serological disease screening. The company develops and commercializes Mosaiq automation platform. Its product portfolio includes Reagent Red Blood Cells, Antisera, Whole Blood Controls, and Ancillary Products. The firm operates in Edinburgh, Scotland, Eysins, Switzerland and Newton, Pennsylvania. It derives the majority of its revenue from the United States.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer